 Cory Dunnick
Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Allergic Contact | 37 | 2023 | 63 | 12.340 |
Why?
| | Dermatology | 27 | 2021 | 86 | 7.340 |
Why?
| | Patch Tests | 30 | 2023 | 51 | 4.830 |
Why?
| | Dermatitis, Occupational | 10 | 2023 | 13 | 4.140 |
Why?
| | Allergens | 25 | 2023 | 413 | 3.530 |
Why?
| | Skin Diseases | 11 | 2021 | 122 | 2.420 |
Why?
| | North America | 21 | 2023 | 256 | 1.850 |
Why?
| | Dermatitis, Irritant | 4 | 2021 | 11 | 1.750 |
Why?
| | Education, Medical, Undergraduate | 4 | 2019 | 159 | 1.470 |
Why?
| | Soaps | 3 | 2020 | 10 | 1.460 |
Why?
| | Dermatitis, Contact | 2 | 2020 | 23 | 1.250 |
Why?
| | Skin Neoplasms | 11 | 2020 | 756 | 1.240 |
Why?
| | Melanoma | 9 | 2020 | 619 | 1.210 |
Why?
| | Students, Medical | 4 | 2021 | 262 | 1.200 |
Why?
| | Curriculum | 5 | 2019 | 819 | 1.170 |
Why?
| | Schools, Medical | 2 | 2019 | 120 | 1.090 |
Why?
| | Cosmetics | 2 | 2022 | 7 | 1.010 |
Why?
| | Telemedicine | 7 | 2020 | 662 | 0.980 |
Why?
| | Surface-Active Agents | 2 | 2022 | 79 | 0.930 |
Why?
| | Irritants | 2 | 2021 | 41 | 0.930 |
Why?
| | Leprosy | 3 | 2020 | 10 | 0.900 |
Why?
| | Alopecia Areata | 2 | 2021 | 9 | 0.900 |
Why?
| | Hand Dermatoses | 2 | 2021 | 7 | 0.900 |
Why?
| | Music | 2 | 2021 | 39 | 0.900 |
Why?
| | Anti-Infective Agents, Local | 2 | 2020 | 40 | 0.830 |
Why?
| | Humans | 95 | 2023 | 114623 | 0.810 |
Why?
| | Nickel | 4 | 2023 | 50 | 0.810 |
Why?
| | Hair Preparations | 1 | 2021 | 2 | 0.770 |
Why?
| | Skin Pigmentation | 1 | 2021 | 39 | 0.750 |
Why?
| | Psoriasis | 5 | 2021 | 74 | 0.750 |
Why?
| | Occupations | 1 | 2021 | 36 | 0.740 |
Why?
| | Retrospective Studies | 26 | 2023 | 12542 | 0.720 |
Why?
| | Hand Hygiene | 1 | 2020 | 7 | 0.710 |
Why?
| | Eczema | 1 | 2021 | 81 | 0.710 |
Why?
| | Facial Dermatoses | 4 | 2021 | 14 | 0.710 |
Why?
| | Severity of Illness Index | 5 | 2018 | 2537 | 0.700 |
Why?
| | Carbanilides | 1 | 2019 | 1 | 0.680 |
Why?
| | Triclosan | 1 | 2019 | 9 | 0.680 |
Why?
| | Education, Medical | 2 | 2019 | 215 | 0.670 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 975 | 0.660 |
Why?
| | Sunscreening Agents | 5 | 2023 | 17 | 0.640 |
Why?
| | Internship and Residency | 8 | 2018 | 926 | 0.640 |
Why?
| | Global Health | 9 | 2020 | 287 | 0.620 |
Why?
| | Cold Injury | 1 | 2017 | 1 | 0.600 |
Why?
| | Weather | 1 | 2017 | 24 | 0.590 |
Why?
| | Mountaineering | 1 | 2017 | 47 | 0.580 |
Why?
| | Patient Satisfaction | 3 | 2018 | 578 | 0.570 |
Why?
| | United States | 25 | 2020 | 12176 | 0.570 |
Why?
| | Quality of Life | 3 | 2020 | 2353 | 0.530 |
Why?
| | Public Opinion | 1 | 2016 | 59 | 0.520 |
Why?
| | Ultraviolet Rays | 2 | 2017 | 363 | 0.510 |
Why?
| | Keloid | 1 | 2015 | 7 | 0.510 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2015 | 19 | 0.500 |
Why?
| | Clinical Competence | 4 | 2019 | 893 | 0.500 |
Why?
| | Career Choice | 2 | 2016 | 177 | 0.500 |
Why?
| | Physical Examination | 1 | 2016 | 222 | 0.500 |
Why?
| | Prevalence | 9 | 2023 | 2249 | 0.470 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 307 | 0.460 |
Why?
| | Petrolatum | 3 | 2023 | 3 | 0.450 |
Why?
| | Electronic Prescribing | 1 | 2013 | 3 | 0.450 |
Why?
| | Societies, Medical | 5 | 2020 | 663 | 0.420 |
Why?
| | Cannabinoids | 3 | 2020 | 115 | 0.420 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1394 | 0.420 |
Why?
| | Alopecia | 2 | 2023 | 28 | 0.410 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1177 | 0.410 |
Why?
| | Female | 30 | 2023 | 59466 | 0.400 |
Why?
| | Male | 27 | 2023 | 55554 | 0.390 |
Why?
| | Internet | 5 | 2018 | 596 | 0.390 |
Why?
| | Dermatitis, Seborrheic | 2 | 2021 | 4 | 0.380 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 368 | 0.370 |
Why?
| | Quality Improvement | 2 | 2016 | 950 | 0.330 |
Why?
| | Consumer Product Safety | 1 | 2009 | 30 | 0.330 |
Why?
| | Drug Industry | 3 | 2019 | 103 | 0.330 |
Why?
| | Skin | 3 | 2021 | 655 | 0.320 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1342 | 0.320 |
Why?
| | United States Food and Drug Administration | 2 | 2019 | 172 | 0.310 |
Why?
| | Dermatologic Agents | 2 | 2019 | 57 | 0.310 |
Why?
| | Cross-Sectional Studies | 9 | 2023 | 4405 | 0.300 |
Why?
| | Adult | 19 | 2023 | 30528 | 0.300 |
Why?
| | Young Adult | 9 | 2023 | 10455 | 0.290 |
Why?
| | Publishing | 2 | 2019 | 124 | 0.280 |
Why?
| | Conflict of Interest | 2 | 2019 | 119 | 0.280 |
Why?
| | Electronic Health Records | 1 | 2013 | 800 | 0.280 |
Why?
| | Incidence | 4 | 2020 | 2311 | 0.270 |
Why?
| | Trace Elements | 1 | 2006 | 45 | 0.250 |
Why?
| | Glucosides | 2 | 2022 | 36 | 0.250 |
Why?
| | Biomedical Research | 3 | 2016 | 585 | 0.250 |
Why?
| | Health Personnel | 2 | 2020 | 574 | 0.240 |
Why?
| | Health Education | 2 | 2017 | 323 | 0.230 |
Why?
| | Periodicals as Topic | 2 | 2018 | 181 | 0.220 |
Why?
| | Cost of Illness | 5 | 2020 | 254 | 0.220 |
Why?
| | Hair Dyes | 1 | 2023 | 2 | 0.220 |
Why?
| | Chlorhexidine | 2 | 2023 | 22 | 0.220 |
Why?
| | Colorado | 4 | 2019 | 4099 | 0.220 |
Why?
| | Drugs, Generic | 1 | 2023 | 18 | 0.210 |
Why?
| | Thiazoles | 1 | 2023 | 110 | 0.210 |
Why?
| | Adolescent | 7 | 2023 | 17831 | 0.210 |
Why?
| | Child | 7 | 2023 | 18404 | 0.200 |
Why?
| | Sunburn | 2 | 2019 | 25 | 0.200 |
Why?
| | Registries | 3 | 2021 | 1767 | 0.200 |
Why?
| | Plant Extracts | 2 | 2021 | 154 | 0.200 |
Why?
| | Resins, Plant | 1 | 2021 | 3 | 0.200 |
Why?
| | Dental Implants | 1 | 2022 | 9 | 0.200 |
Why?
| | Contact Lens Solutions | 1 | 2021 | 1 | 0.190 |
Why?
| | Dermatitis, Phototoxic | 1 | 2021 | 3 | 0.190 |
Why?
| | Palmitic Acids | 1 | 2021 | 9 | 0.190 |
Why?
| | Office Visits | 2 | 2018 | 79 | 0.190 |
Why?
| | Ammonium Sulfate | 1 | 2021 | 12 | 0.190 |
Why?
| | Ethanolamines | 1 | 2021 | 19 | 0.190 |
Why?
| | Dental Materials | 1 | 2022 | 52 | 0.190 |
Why?
| | Clothing | 1 | 2021 | 19 | 0.190 |
Why?
| | Hydrogen Peroxide | 1 | 2023 | 288 | 0.190 |
Why?
| | Aircraft | 1 | 2021 | 26 | 0.190 |
Why?
| | Carcinoma, Basal Cell | 3 | 2020 | 68 | 0.190 |
Why?
| | Coloring Agents | 1 | 2021 | 72 | 0.190 |
Why?
| | Ophthalmic Solutions | 1 | 2021 | 66 | 0.190 |
Why?
| | Amides | 1 | 2021 | 86 | 0.180 |
Why?
| | Oxidants | 1 | 2021 | 112 | 0.180 |
Why?
| | Physicians | 2 | 2019 | 772 | 0.180 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 49 | 0.180 |
Why?
| | Pyrroles | 1 | 2021 | 181 | 0.180 |
Why?
| | Subcutaneous Tissue | 1 | 2020 | 17 | 0.180 |
Why?
| | Age Distribution | 2 | 2019 | 342 | 0.180 |
Why?
| | Cannabidiol | 1 | 2021 | 60 | 0.180 |
Why?
| | Piperidines | 1 | 2021 | 160 | 0.180 |
Why?
| | Middle Aged | 9 | 2023 | 26719 | 0.180 |
Why?
| | Endemic Diseases | 1 | 2020 | 23 | 0.170 |
Why?
| | Health Care Costs | 2 | 2015 | 381 | 0.170 |
Why?
| | Masks | 1 | 2020 | 46 | 0.170 |
Why?
| | Benzethonium | 1 | 2019 | 1 | 0.170 |
Why?
| | Xylenes | 1 | 2019 | 7 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 67 | 0.170 |
Why?
| | Benzalkonium Compounds | 1 | 2019 | 14 | 0.170 |
Why?
| | Marketing | 1 | 2019 | 24 | 0.170 |
Why?
| | Developed Countries | 2 | 2017 | 28 | 0.170 |
Why?
| | Chemoprevention | 2 | 2016 | 88 | 0.170 |
Why?
| | Consultants | 1 | 2019 | 13 | 0.170 |
Why?
| | Authorship | 1 | 2019 | 31 | 0.160 |
Why?
| | Child, Preschool | 3 | 2023 | 9108 | 0.160 |
Why?
| | Bibliometrics | 1 | 2019 | 44 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 238 | 0.160 |
Why?
| | Quality of Health Care | 2 | 2013 | 573 | 0.160 |
Why?
| | Drug Approval | 1 | 2019 | 78 | 0.160 |
Why?
| | Pyrimidines | 1 | 2021 | 376 | 0.160 |
Why?
| | Primary Prevention | 1 | 2020 | 172 | 0.160 |
Why?
| | Financial Support | 1 | 2018 | 18 | 0.160 |
Why?
| | Water | 1 | 2021 | 396 | 0.150 |
Why?
| | Environmental Monitoring | 1 | 2020 | 254 | 0.150 |
Why?
| | Consumer Health Information | 1 | 2018 | 47 | 0.150 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 5 | 0.150 |
Why?
| | Surveys and Questionnaires | 4 | 2020 | 4620 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2021 | 255 | 0.150 |
Why?
| | Video Recording | 1 | 2018 | 143 | 0.150 |
Why?
| | Developing Countries | 2 | 2017 | 235 | 0.150 |
Why?
| | Hyperpigmentation | 1 | 2018 | 11 | 0.150 |
Why?
| | Congresses as Topic | 1 | 2019 | 195 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2020 | 739 | 0.150 |
Why?
| | Outpatients | 1 | 2020 | 326 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
| | Sex Factors | 2 | 2020 | 1715 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 577 | 0.140 |
Why?
| | Social Networking | 1 | 2017 | 30 | 0.140 |
Why?
| | Photography | 1 | 2017 | 88 | 0.140 |
Why?
| | Travel | 1 | 2017 | 121 | 0.140 |
Why?
| | Substance P | 1 | 1996 | 44 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2020 | 345 | 0.130 |
Why?
| | Age Factors | 1 | 2023 | 2894 | 0.130 |
Why?
| | Reward | 1 | 2018 | 211 | 0.130 |
Why?
| | Aged | 7 | 2023 | 19061 | 0.130 |
Why?
| | Micronutrients | 1 | 2016 | 78 | 0.130 |
Why?
| | Mobile Applications | 1 | 2018 | 140 | 0.130 |
Why?
| | Access to Information | 1 | 2016 | 47 | 0.130 |
Why?
| | Ear Auricle | 1 | 2015 | 11 | 0.130 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 206 | 0.120 |
Why?
| | Community Health Services | 1 | 2017 | 212 | 0.120 |
Why?
| | Scalp | 1 | 2015 | 29 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 338 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 330 | 0.120 |
Why?
| | Keratinocytes | 1 | 2016 | 216 | 0.120 |
Why?
| | Neovascularization, Physiologic | 1 | 1996 | 173 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2017 | 410 | 0.120 |
Why?
| | Cannabis | 1 | 2021 | 384 | 0.120 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2015 | 106 | 0.120 |
Why?
| | Carcinoma | 1 | 2016 | 198 | 0.120 |
Why?
| | Shoulder | 1 | 2015 | 85 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2018 | 478 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2015 | 182 | 0.120 |
Why?
| | Disease Management | 1 | 2018 | 560 | 0.120 |
Why?
| | National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) | 1 | 2014 | 1 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2021 | 9084 | 0.120 |
Why?
| | Chlorpromazine | 1 | 2014 | 5 | 0.120 |
Why?
| | Corneal Opacity | 1 | 2014 | 6 | 0.120 |
Why?
| | Research Support as Topic | 1 | 2015 | 108 | 0.120 |
Why?
| | Pigmentation Disorders | 1 | 2014 | 7 | 0.120 |
Why?
| | Financing, Government | 1 | 2014 | 40 | 0.120 |
Why?
| | Wound Healing | 1 | 1996 | 258 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 299 | 0.110 |
Why?
| | Universities | 1 | 2016 | 339 | 0.110 |
Why?
| | Altitude | 1 | 2017 | 432 | 0.110 |
Why?
| | Social Support | 1 | 2017 | 528 | 0.110 |
Why?
| | Cornea | 1 | 2014 | 102 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2762 | 0.110 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 328 | 0.110 |
Why?
| | Burns | 1 | 1996 | 237 | 0.110 |
Why?
| | Research Report | 1 | 2013 | 75 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 373 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1317 | 0.100 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 184 | 0.100 |
Why?
| | Acne Vulgaris | 1 | 2011 | 20 | 0.100 |
Why?
| | Social Media | 1 | 2014 | 131 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1214 | 0.090 |
Why?
| | Quality-Adjusted Life Years | 3 | 2017 | 101 | 0.090 |
Why?
| | Databases, Factual | 3 | 2020 | 1124 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 1815 | 0.090 |
Why?
| | Needs Assessment | 1 | 2011 | 314 | 0.080 |
Why?
| | Infant | 2 | 2019 | 7959 | 0.080 |
Why?
| | Information Dissemination | 1 | 2010 | 186 | 0.080 |
Why?
| | Risk Factors | 4 | 2021 | 8628 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2010 | 680 | 0.070 |
Why?
| | Disability Evaluation | 2 | 2017 | 271 | 0.060 |
Why?
| | Phenylenediamines | 1 | 2023 | 5 | 0.060 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2023 | 24 | 0.050 |
Why?
| | Benzophenones | 1 | 2023 | 16 | 0.050 |
Why?
| | Interferon-beta | 1 | 2023 | 79 | 0.050 |
Why?
| | Lanolin | 1 | 2022 | 1 | 0.050 |
Why?
| | Europe | 1 | 2023 | 334 | 0.050 |
Why?
| | Dentistry | 1 | 2022 | 12 | 0.050 |
Why?
| | Adhesives | 1 | 2021 | 11 | 0.050 |
Why?
| | Chorioallantoic Membrane | 1 | 2021 | 3 | 0.050 |
Why?
| | Patient-Centered Care | 2 | 2018 | 473 | 0.050 |
Why?
| | Administration, Topical | 1 | 2021 | 138 | 0.050 |
Why?
| | Spider Bites | 1 | 2001 | 10 | 0.050 |
Why?
| | Neck | 1 | 2021 | 83 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2021 | 258 | 0.050 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.040 |
Why?
| | Global Burden of Disease | 1 | 2020 | 15 | 0.040 |
Why?
| | Prognosis | 2 | 2018 | 3328 | 0.040 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 88 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2021 | 1016 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 165 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 155 | 0.040 |
Why?
| | Sunbathing | 1 | 2018 | 13 | 0.040 |
Why?
| | Manufacturing Industry | 1 | 2018 | 4 | 0.040 |
Why?
| | Dermatologists | 1 | 2018 | 1 | 0.040 |
Why?
| | Time Factors | 2 | 2019 | 6112 | 0.040 |
Why?
| | Aerosols | 1 | 2019 | 150 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 728 | 0.040 |
Why?
| | Transportation | 1 | 2018 | 44 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 38 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 305 | 0.040 |
Why?
| | Thorax | 1 | 2018 | 40 | 0.040 |
Why?
| | China | 1 | 2018 | 161 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2018 | 125 | 0.040 |
Why?
| | Research Design | 1 | 2023 | 928 | 0.040 |
Why?
| | Smartphone | 1 | 2018 | 72 | 0.040 |
Why?
| | Patient Care | 1 | 2018 | 101 | 0.040 |
Why?
| | Recurrence | 1 | 2020 | 935 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 951 | 0.040 |
Why?
| | Polypodium | 1 | 2016 | 1 | 0.040 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 6 | 0.030 |
Why?
| | Balsams | 1 | 2016 | 2 | 0.030 |
Why?
| | Perfume | 1 | 2016 | 3 | 0.030 |
Why?
| | Bacitracin | 1 | 2016 | 6 | 0.030 |
Why?
| | Waiting Lists | 1 | 2018 | 211 | 0.030 |
Why?
| | Neomycin | 1 | 2016 | 7 | 0.030 |
Why?
| | Propylene Glycol | 1 | 2016 | 9 | 0.030 |
Why?
| | p-Aminohippuric Acid | 1 | 1996 | 6 | 0.030 |
Why?
| | Culture Techniques | 1 | 1996 | 78 | 0.030 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 1996 | 8 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2017 | 89 | 0.030 |
Why?
| | Ketoglutaric Acids | 1 | 1996 | 15 | 0.030 |
Why?
| | Formaldehyde | 1 | 2016 | 46 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1448 | 0.030 |
Why?
| | Cobalt | 1 | 2016 | 46 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 63 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2020 | 288 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 768 | 0.030 |
Why?
| | Neuropeptides | 1 | 1996 | 65 | 0.030 |
Why?
| | Gold | 1 | 2016 | 106 | 0.030 |
Why?
| | Personnel Selection | 1 | 2016 | 62 | 0.030 |
Why?
| | Leadership | 1 | 2018 | 292 | 0.030 |
Why?
| | Syphilis | 1 | 2014 | 26 | 0.030 |
Why?
| | Measles | 1 | 2014 | 38 | 0.030 |
Why?
| | Dengue | 1 | 2014 | 59 | 0.030 |
Why?
| | Chickenpox | 1 | 2014 | 93 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2016 | 228 | 0.030 |
Why?
| | Patient Advocacy | 1 | 2014 | 66 | 0.030 |
Why?
| | Health Communication | 1 | 2014 | 40 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2015 | 275 | 0.030 |
Why?
| | Health Status | 1 | 2018 | 722 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1840 | 0.030 |
Why?
| | Chronic Disease | 1 | 2018 | 1578 | 0.030 |
Why?
| | Disabled Persons | 1 | 2014 | 133 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2018 | 761 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1629 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 274 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 539 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1477 | 0.020 |
Why?
| | Schizophrenia | 1 | 2014 | 414 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 2967 | 0.020 |
Why?
| | Kidney | 1 | 1996 | 1188 | 0.020 |
Why?
| | Medicaid | 1 | 2013 | 406 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1691 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 5517 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 665 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 6217 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6344 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 5043 | 0.020 |
Why?
| | Mice | 1 | 2017 | 14860 | 0.010 |
Why?
| | Animals | 2 | 2017 | 31694 | 0.010 |
Why?
| | Ouabain | 1 | 1996 | 15 | 0.010 |
Why?
| | Glutarates | 1 | 1996 | 6 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1996 | 241 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 1842 | 0.010 |
Why?
| | Rats | 1 | 1996 | 4958 | 0.000 |
Why?
|
|
Dunnick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|